Avadel announces new positive data for once-at-bedtime ft218 for narcolepsy and once-nightly dosing preference among patients and clinicians at world sleep 2022

Dublin, ireland, march 11, 2022 (globe newswire) -- avadel pharmaceuticals plc (nasdaq: avdl), a company focused on transforming medicines to transform lives, today announced new data will be presented in eight posters at the world sleep 2022 congress in rome. the presentations will feature results from a discrete choice experiment (dce) designed to characterize and quantify drivers of preferences for attributes associated with oxybate treatments for narcolepsy, with a background survey providing patient and clinician perspectives on narcolepsy disease burden, treatment approaches and satisfaction with current narcolepsy treatment options. new post-hoc data from the completed pivotal phase 3 rest-on clinical trial of ft218 and interim data from the ongoing restore open-label extension/switch study of ft218 will also be presented.
AVDL Ratings Summary
AVDL Quant Ranking